{"id":"hpp2003-3","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Hypoglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HPP2003-3 activates glucagon-like peptide-1 (GLP-1) receptors on pancreatic beta cells and alpha cells, stimulating glucose-dependent insulin secretion while suppressing glucagon secretion. The extended half-life formulation allows for less frequent dosing compared to shorter-acting GLP-1 agonists, providing sustained glycemic control over extended intervals.","oneSentence":"HPP2003-3 is a long-acting GLP-1 receptor agonist designed to improve glycemic control in diabetes by enhancing insulin secretion and reducing glucagon release.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:45:31.536Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06438172","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential Hypertension","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2024-03-25","conditions":"Hypertension","enrollment":249},{"nctId":"NCT05362110","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2022-05-16","conditions":"Hypertension","enrollment":361},{"nctId":"NCT04959305","phase":"PHASE2","title":"A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2021-04-22","conditions":"Hypertension","enrollment":245}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HPP2003-3","genericName":"HPP2003-3","companyName":"Hanmi Pharmaceutical Company Limited","companyId":"hanmi-pharmaceutical-company-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HPP2003-3 is a long-acting GLP-1 receptor agonist designed to improve glycemic control in diabetes by enhancing insulin secretion and reducing glucagon release. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}